Pieris Pharmaceuticals Investor Presentation — February 2018

Document content

Investor Presentation

(Nasdaq: PIRS) Forward Looking Statements

Statements in this presentation that are not descriptions of historical facts are forward -looking statements that are based on m anagement’s

current expectations and assumptions and are subject to risks and uncertainties. In some cases, you can identify forward -looking statements

by terminology including “anticipates,” “believes,” “can,” “continue,” “could,” “estimates,” “expects,” “intends,” “may,” “pl ans,” “potential,”

“predicts,” “projects,” “should,” “will,” “would” or the negative of these terms or other comparable terminology. Factors tha t could cause actual

results to differ materially from those currently anticipated include, without limitation, risks relating to the results of o ur research and

development activities, including uncertainties relating to the discovery of potential drug candidates and the preclinical an d clinical testing of

our drug candidates; the early stage of our drug candidates presently under development; our ability to obtain and, if obtain ed, maintain

regulatory approval of our current drug candidates and any of our other future drug candidates; our need for substantial addi tional funds in

order to continue our operations and the uncertainty of whether we will be able to obtain the funding we need; our future fin ancial performance;

our ability to retain or hire key scientific or management personnel; our ability to protect our intellectual property rights that are valuable to our

business, including patent and other intellectual property rights; our dependence on third -party manufacturers, suppliers, resea rch

organizations, testing laboratories and other potential collaborators; our ability to successfully market and sell our drug c andidates in the future

as needed; the size and growth of the potential markets for any of our approved drug candidates, and the rate and degree of m arket

acceptance of any of our approved drug candidates; developments and projections relating to our competitors and our industry; our ability to

establish collaborations; our expectations regarding the time which we will be an emerging growth company under the JOBS Act ; our use of

proceeds from this offering; regulatory developments in the U.S. and foreign countries; and other factors that are described more fully in our

Annual Report on form 10 -K filed with the SEC on March 30, 2017. In light of these risks, uncertainties and assumptions, the for ward -looking

statements regarding future events and circumstances discussed in this report may not occur and actual results could differ m aterially and